CoV2-06
An anti-Spike (SARS-CoV-2) human monoclonal antibody.
General information
CoV2-06 is a human monoclonal antibody targeting Spike protein RBD (SARS-CoV-2). It was identified using single-chain variable fragment phage display technique. Its epitope does not overlap with the CoV2-14's one and these two antibodies were, therefore, used together in a cocktail to neutralize SARS-CoV-2 infection in an animal model. This antibody cocktail prevents viral neutralization escape (Ku et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
Spike protein Biophysical assay Animal model In vitro Antibody |
in vitro binding assay; in vitro biophysical assay; Vero cells; Vero E6 cells; TMPRSS2-expressing Vero E6 cells; BALB/c mice; SARS-CoV-2 S pseudovirus; SARS-CoV-2 mouse-adapted strain CMA-3; SARS-CoV-2 clinical isolate USA/WA1/2020 | 12.12 | Binds to RBD of SARS-CoV-2 Spike protein and neutralizes SARS-CoV-2 live virus in vitro with NT50 of 0.15 μg/ml. CoV2-06 shows synergy with CoV2-14 in viral neutralization. At 20 mg/kg the combination of these two antibodies protected mice from infection when administered either prophylactically or therapeutically. |
Jan/20/2021 |
